Anti-FGFR3 activation mutation therapy is approved for the treatment of bladder cancer carrying FGFR3 activation mutation, but we did not observe activation mutation of FGFR3 in these specimens. The gene discussed is FGFR3; the disease is urinary bladder carcinoma.